A once-weekly GLP-1/glucagon dual receptor agonist based on the gut hormone oxyntomodulin. It has been approved in China for weight management and remains investigational in other regions.
Mechanism under study
Derived from oxyntomodulin, mazdutide activates both GLP-1 and glucagon receptors — an approach intended to reduce appetite while increasing energy expenditure.
Research-reported dosing
Approved in China (2025) for chronic weight management; investigational elsewhere. Phase 3 programs studied once-weekly subcutaneous doses in roughly the 4-6 mg range.
5 mg vial + 1 mL bacteriostatic water = 5000 mcg/mL.
A 4 mg dose ≈ 80 units (50 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Mazdutide FAQ
What is Mazdutide?
A once-weekly GLP-1/glucagon dual receptor agonist based on the gut hormone oxyntomodulin. It has been approved in China for weight management and remains investigational in other regions.
What is the half-life of Mazdutide?
Long — supports once-weekly subcutaneous dosing.
What is the research-reported dosing for Mazdutide?
Approved in China (2025) for chronic weight management; investigational elsewhere. Phase 3 programs studied once-weekly subcutaneous doses in roughly the 4-6 mg range.
How is Mazdutide reconstituted?
5 mg vial + 1 mL bacteriostatic water = 5000 mcg/mL.
Is Mazdutide FDA-approved?
Mazdutide has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Related peptides
Survodutide
GLP-1 / glucagon dual receptor agonist
An investigational once-weekly peptide that activates both the GLP-1 and glucagon receptors, studied for obesity and metabolic liver disease (MASH).
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
Tirzepatide
Dual GIP / GLP-1 receptor agonist
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.